| __timestamp | Bausch Health Companies Inc. | Telix Pharmaceuticals Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 2254600000 | 22622695 |
| Thursday, January 1, 2015 | 2645000000 | 24863028 |
| Friday, January 1, 2016 | 2611000000 | 21351001 |
| Sunday, January 1, 2017 | 2548000000 | 53837297 |
| Monday, January 1, 2018 | 2351000000 | 16080096 |
| Tuesday, January 1, 2019 | 2350000000 | 18525736 |
| Wednesday, January 1, 2020 | 2249000000 | 2024000 |
| Friday, January 1, 2021 | 2394000000 | 2548000 |
| Saturday, January 1, 2022 | 2364000000 | 61556000 |
| Sunday, January 1, 2023 | 2559000000 | 188157000 |
Unleashing insights
In the ever-evolving pharmaceutical landscape, understanding cost structures is crucial. Bausch Health Companies Inc. and Telix Pharmaceuticals Limited, two prominent players, offer a fascinating study in contrasts. From 2014 to 2023, Bausch Health's cost of revenue remained relatively stable, averaging around $2.4 billion annually. This consistency reflects their established market presence and operational efficiency. In contrast, Telix Pharmaceuticals, a newer entrant, saw a dramatic increase in cost of revenue, skyrocketing from approximately $2 million in 2020 to nearly $188 million in 2023. This 9,300% surge underscores Telix's rapid expansion and investment in growth. While Bausch Health's costs peaked in 2015, Telix's costs have shown a consistent upward trend, highlighting their aggressive market penetration strategy. This data not only reveals the financial dynamics of these companies but also provides insights into their strategic priorities over the past decade.
Cost of Revenue Comparison: AbbVie Inc. vs Telix Pharmaceuticals Limited
Cost Insights: Breaking Down Sanofi and Telix Pharmaceuticals Limited's Expenses
Cost of Revenue: Key Insights for Gilead Sciences, Inc. and Telix Pharmaceuticals Limited
GSK plc vs Telix Pharmaceuticals Limited: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: BioMarin Pharmaceutical Inc. and Telix Pharmaceuticals Limited
BioMarin Pharmaceutical Inc. vs Bausch Health Companies Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Exelixis, Inc. and Telix Pharmaceuticals Limited
Comparing Cost of Revenue Efficiency: Cytokinetics, Incorporated vs Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited vs Taro Pharmaceutical Industries Ltd.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Amneal Pharmaceuticals, Inc. vs Bausch Health Companies Inc.
Cost Insights: Breaking Down Bausch Health Companies Inc. and Vericel Corporation's Expenses
Comparing Cost of Revenue Efficiency: Bausch Health Companies Inc. vs Mesoblast Limited